FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

NCT04699643 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: EVER4010001

Sponsor

EverNov Medicines (Zhuhai Hengqin) Co., Ltd

Collaborators

[object Object]